Quadrant Private Wealth Management LLC Has $763,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Quadrant Private Wealth Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,256 shares of the biopharmaceutical company’s stock after selling 385 shares during the quarter. Quadrant Private Wealth Management LLC’s holdings in Gilead Sciences were worth $763,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. AMF Tjanstepension AB raised its stake in Gilead Sciences by 14.7% during the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock worth $33,645,000 after buying an additional 51,390 shares during the period. Creative Planning raised its stake in Gilead Sciences by 16.1% during the 3rd quarter. Creative Planning now owns 219,045 shares of the biopharmaceutical company’s stock worth $18,365,000 after buying an additional 30,451 shares during the period. Swedbank AB raised its stake in Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after buying an additional 189,622 shares during the period. SPC Financial Inc. raised its stake in Gilead Sciences by 11.0% during the 3rd quarter. SPC Financial Inc. now owns 5,530 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 550 shares during the period. Finally, nVerses Capital LLC acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $25,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 710,500 shares of company stock worth $67,684,956 over the last three months. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 1.8 %

NASDAQ GILD opened at $104.08 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a market capitalization of $129.71 billion, a PE ratio of 1,156.44, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $106.69. The business’s 50-day moving average is $93.63 and its 200 day moving average is $87.37.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 3.04%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Wall Street Analyst Weigh In

A number of brokerages have commented on GILD. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Robert W. Baird upped their target price on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Piper Sandler increased their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday. Eleven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.33.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.